pSivida begins phase 2 study of steroid blocker as eye treatment

By Lisa Kerner

Charlotte, N.C., Sept. 19 - pSivida Ltd. began a phase 2 clinical trial of Mifepristone (RU486), a steroid blocker, as an eye drop treatment in 45 patients with steroid-associated elevated intraocular pressure.

Similar drugs include Bausch & Lomb's marketed Retisert back-of-the-eye treatment for uveitis, a leading cause of blindness, and Alimera Sciences' licensed Medidur in phase 3 clinical trials for the treatment of diabetic macular edema.

Boston-based pSivida, a global bio-nanotech company, has licensed the technologies underlying both of these products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.